Business
AngioSoma's Corporate Focus
AngioSoma's Corporate Focus.
About this update from Globestar Therapeutics Corporation
[{"type":"text","content":"\n \n AngioSoma, Inc. (OTCQB:SOAN), previously known as First Titan Corp. (the \n 'Company', 'we', and 'our'), changed our corporate \n name and focus to that of a clinical stage biopharmaceutical company \n introducing an exciting new treatment for one of the world's most \n insidious and pervasive diseases, peripheral artery disease ('PAD'). The \n introduction of this new drug, Liprostin™, a liposomal controlled \n release encapsulation of ProstaglandinE1 (PGE1), will greatly improve \n the effectiveness of the drug and of current standard-of-care \n treatments, especially when used with endovascular interventions such as \n transluminal percutaneous angioplasty, stenting and atherectomy \n interventions in the treatment of PAD. The Company's strengths include \n our research team, flagship product Liprostin™, intellectual property \n pipeline, and legacy oil & gas assets.\n \n \n Our research team, headed by Chairman Emeritus Dr. David P. \n Summers, PhD, are a multi-talented seasoned collection of applied \n scientists and medical field specialists assembled to produce product \n and market results – “this isn't their first rodeo!” Dr. \n Summers’s biotechnical experience as both an engineer and biotechnical \n scientist bringing intellectual property to market is extensive, \n spanning multiple decades. “Working with Dr. Summers is an absolute \n pleasure! His long history of leading research teams from product \n & technology conceptualization, through product development, and then to \n product sales is amazing,” said Alex Blankenship, AngioSoma, Inc.'s \n CEO.\n \n \n Liprostin™, our flagship product, is an FDA-approved product in a \n new controlled delivery system, a sterically stable liposome that has \n made our product, the well-known generic ProstaglandinE1 (PGE1), a brand \n new drug with a brand new controlled delivery. The Liprostin™ market is \n a very large multi-billion-dollar international market. There are many \n derivative treatments such as diabetes, peripheral neuropathies, and \n various vascular disorders that may be candidates for treatment once FDA \n approval is obtained, and information amassed by our research team will \n provide a continuous stream of intellectual property ('IP') \n yielding future patent protection and future ...